Polaris Pharmaceuticals-KY (6550) Announces Board Re-election at Annual General Meeting
Polaris Pharmaceuticals-KY (6550) announced on May 15, 115 (2026) that its 115th annual general meeting of shareholders resulted in the full re-election of its board of directors, including independent directors. This change is due to the expiration of the current term. The new board includes re-elected members such as Chen Xian-Zhe, who will continue as Chairman, and new appointments like Zhou Hong-Jie, who holds a PhD in Chemistry and Chemical Biology from Harvard University. Other new directors and independent directors were also elected. The previous term ran from September 26, 112 (2023) to June 11, 115 (2026).
📋 Article Processing Timeline
- 📰 Published: May 16, 2026 at 12:57
- 🔍 Collected: May 16, 2026 at 12:57 (0 min after Published)
- 🤖 AI Analyzed: May 16, 2026 at 14:45 (1h 48m after Collected)
Announcement Date: 115/05/16
Spokesperson Date: 115/05/15
Spokesperson Time: 211538
Company Code: 6550
Company Name: Polaris Pharmaceuticals-KY
Subject: Announcement of the full re-election of directors (including independent directors) at the company's 115th Annual General Meeting of Shareholders
Compliance Clause: Clause 6
Date of Fact Occurrence: 115/05/15
Explanation:
1. Date of Change: 115/05/15
2. Type of Appointed or Changed Personnel (Please enter Corporate Director, Corporate Supervisor, Independent Director, Natural Person Director, or Natural Person Supervisor): Corporate Director, Natural Person Director, Independent Director
3. Titles and Names of Former Personnel:
Polaris Pharmaceuticals Group Director / Chen Xian-Zhe
Polaris Pharmaceuticals Group Director / Digital Capital Inc. Representative: Wei Shao-Jun
Polaris Pharmaceuticals Group Director / Mai Investment Co., Ltd. Representative: Cai Gao-Zhong
Polaris Pharmaceuticals Group Director / Chen Hong-Wen
Polaris Pharmaceuticals Group Independent Director / Zhao Ying-Cheng
Polaris Pharmaceuticals Group Independent Director / Wei Zong-De
Polaris Pharmaceuticals Group Independent Director / Wen (日皿) Guo Lan
Polaris Pharmaceuticals Group Independent Director / Zeng Guo-Hua
4. Brief Resumes of Former Personnel:
Chen Xian-Zhe / Company Director
Chen Hong-Wen / Company Director
Digital Capital Inc. Representative: Wei Shao-Jun / Company Director
Mai Investment Co., Ltd. Representative: Cai Gao-Zhong / Company Director
Zhao Ying-Cheng / Company Independent Director
Wei Zong-De / Company Independent Director
Wen (日皿) Guo Lan / Company Independent Director
Zeng Guo-Hua / Company Independent Director
5. Titles and Names of New Personnel:
Director Nominees:
Chen Xian-Zhe Director
Corporate Director: Digital Capital Inc. Representative: Wei Shao-Jun
Corporate Director: Mai Investment Co., Ltd. Representative: Cai Gao-Zhong
Zhou Hong-Jie Director
Independent Director Nominees:
Zhao Ying-Cheng Independent Director
Zhang Yi-Fang Independent Director
Zhang Zhi-Gang Independent Director
Di Shi-Jie Independent Director
6. Brief Resumes of New Personnel:
Director Nominees:
Chen Xian-Zhe Director / Company Chairman
Corporate Director: Digital Capital Inc. Representative: Wei Shao-Jun
Corporate Director: Mai Investment Co., Ltd. Representative: Cai Gao-Zhong
Zhou Hong-Jie Director / PhD in Chemistry and Chemical Biology, Harvard University, USA
Independent Director Nominees:
Zhao Ying-Cheng Independent Director / Company Independent Director
Zhang Yi-Fang Independent Director / Vice President, Mackay Taitung Branch
Zhang Zhi-Gang Independent Director / CEO, Zhong En Biomedical
Di Shi-Jie Independent Director / Associate Professor, University of Hong Kong
7. Change Details (Please enter 'Resignation', 'Dismissal', 'Term Expiration', 'Death', or 'New Appointment'): Term Expiration
8. Reason for Change: Full re-election due to term expiration.
9. Shareholding of New Appointees at the Time of Election:
Director Chen Xian-Zhe: 49,500,000 shares
Corporate Director: Digital Capital Inc.: 376,086,333 shares
Corporate Director: Mai Investment Co., Ltd.: 40,527,138 shares
Director Zhou Hong-Jie: 0 shares
Independent Director Zhang Yi-Fang: 0 shares
Independent Director Zhang Zhi-Gang: 0 shares
Independent Director Di Shi-Jie: 0 shares
Independent Director Zhao Ying-Cheng: 0 shares
10. Original Term (e.g., xx/xx/xx ~ xx/xx/xx): 112/09/26 ~ 115/06/11
11. Effective Date of New Appointment: 115/05/15
12. Proportion of Director Changes within the Same Term: Not applicable as it is a full re-election due to term expiration.
13. Proportion of Independent Director Changes within the Same Term: Not applicable as it is a full re-election due to term expiration.
14. Proportion of Supervisor Changes within the Same Term: Not applicable.
15. Whether Directors Constituting One-Third or More Have Changed (Please enter Yes or No): Not applicable as it is a full re-election due to term expiration.
16. Other Matters to be Noted (If the subject of the event or resolution is a publicly issued company or above, this major information also complies with Article 7, Clause 6 of the Enforcement Rules of the Securities Transaction Act regarding matters that have a significant impact on shareholder rights or securities prices):
None
Spokesperson Date: 115/05/15
Spokesperson Time: 211538
Company Code: 6550
Company Name: Polaris Pharmaceuticals-KY
Subject: Announcement of the full re-election of directors (including independent directors) at the company's 115th Annual General Meeting of Shareholders
Compliance Clause: Clause 6
Date of Fact Occurrence: 115/05/15
Explanation:
1. Date of Change: 115/05/15
2. Type of Appointed or Changed Personnel (Please enter Corporate Director, Corporate Supervisor, Independent Director, Natural Person Director, or Natural Person Supervisor): Corporate Director, Natural Person Director, Independent Director
3. Titles and Names of Former Personnel:
Polaris Pharmaceuticals Group Director / Chen Xian-Zhe
Polaris Pharmaceuticals Group Director / Digital Capital Inc. Representative: Wei Shao-Jun
Polaris Pharmaceuticals Group Director / Mai Investment Co., Ltd. Representative: Cai Gao-Zhong
Polaris Pharmaceuticals Group Director / Chen Hong-Wen
Polaris Pharmaceuticals Group Independent Director / Zhao Ying-Cheng
Polaris Pharmaceuticals Group Independent Director / Wei Zong-De
Polaris Pharmaceuticals Group Independent Director / Wen (日皿) Guo Lan
Polaris Pharmaceuticals Group Independent Director / Zeng Guo-Hua
4. Brief Resumes of Former Personnel:
Chen Xian-Zhe / Company Director
Chen Hong-Wen / Company Director
Digital Capital Inc. Representative: Wei Shao-Jun / Company Director
Mai Investment Co., Ltd. Representative: Cai Gao-Zhong / Company Director
Zhao Ying-Cheng / Company Independent Director
Wei Zong-De / Company Independent Director
Wen (日皿) Guo Lan / Company Independent Director
Zeng Guo-Hua / Company Independent Director
5. Titles and Names of New Personnel:
Director Nominees:
Chen Xian-Zhe Director
Corporate Director: Digital Capital Inc. Representative: Wei Shao-Jun
Corporate Director: Mai Investment Co., Ltd. Representative: Cai Gao-Zhong
Zhou Hong-Jie Director
Independent Director Nominees:
Zhao Ying-Cheng Independent Director
Zhang Yi-Fang Independent Director
Zhang Zhi-Gang Independent Director
Di Shi-Jie Independent Director
6. Brief Resumes of New Personnel:
Director Nominees:
Chen Xian-Zhe Director / Company Chairman
Corporate Director: Digital Capital Inc. Representative: Wei Shao-Jun
Corporate Director: Mai Investment Co., Ltd. Representative: Cai Gao-Zhong
Zhou Hong-Jie Director / PhD in Chemistry and Chemical Biology, Harvard University, USA
Independent Director Nominees:
Zhao Ying-Cheng Independent Director / Company Independent Director
Zhang Yi-Fang Independent Director / Vice President, Mackay Taitung Branch
Zhang Zhi-Gang Independent Director / CEO, Zhong En Biomedical
Di Shi-Jie Independent Director / Associate Professor, University of Hong Kong
7. Change Details (Please enter 'Resignation', 'Dismissal', 'Term Expiration', 'Death', or 'New Appointment'): Term Expiration
8. Reason for Change: Full re-election due to term expiration.
9. Shareholding of New Appointees at the Time of Election:
Director Chen Xian-Zhe: 49,500,000 shares
Corporate Director: Digital Capital Inc.: 376,086,333 shares
Corporate Director: Mai Investment Co., Ltd.: 40,527,138 shares
Director Zhou Hong-Jie: 0 shares
Independent Director Zhang Yi-Fang: 0 shares
Independent Director Zhang Zhi-Gang: 0 shares
Independent Director Di Shi-Jie: 0 shares
Independent Director Zhao Ying-Cheng: 0 shares
10. Original Term (e.g., xx/xx/xx ~ xx/xx/xx): 112/09/26 ~ 115/06/11
11. Effective Date of New Appointment: 115/05/15
12. Proportion of Director Changes within the Same Term: Not applicable as it is a full re-election due to term expiration.
13. Proportion of Independent Director Changes within the Same Term: Not applicable as it is a full re-election due to term expiration.
14. Proportion of Supervisor Changes within the Same Term: Not applicable.
15. Whether Directors Constituting One-Third or More Have Changed (Please enter Yes or No): Not applicable as it is a full re-election due to term expiration.
16. Other Matters to be Noted (If the subject of the event or resolution is a publicly issued company or above, this major information also complies with Article 7, Clause 6 of the Enforcement Rules of the Securities Transaction Act regarding matters that have a significant impact on shareholder rights or securities prices):
None
FAQ
What is the company code for Polaris Pharmaceuticals-KY?
The company code is 6550.
When was the annual general meeting held?
The annual general meeting was held on May 15, 115 (2026).
What was the main purpose of the shareholder meeting?
The main purpose was the full re-election of directors, including independent directors, due to the expiration of their terms.
Who are some of the newly elected directors?
Newly elected directors include Chen Xian-Zhe (also Chairman), Digital Capital Inc. (represented by Wei Shao-Jun), Mai Investment Co., Ltd. (represented by Cai Gao-Zhong), and Zhou Hong-Jie. New independent directors include Zhao Ying-Cheng, Zhang Yi-Fang, Zhang Zhi-Gang, and Di Shi-Jie.
What is the tenure of the previous board?
The previous term was from September 26, 112 (2023) to June 11, 115 (2026).